171 related articles for article (PubMed ID: 37828980)
81. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study.
Yuen C; Rezania K; Kelly T; Bishop MR
Immunotherapy; 2021 Oct; 13(15):1261-1269. PubMed ID: 34558978
[TBL] [Abstract][Full Text] [Related]
82. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by
Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865
[TBL] [Abstract][Full Text] [Related]
83. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
[TBL] [Abstract][Full Text] [Related]
84. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
85. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
86. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
[TBL] [Abstract][Full Text] [Related]
87. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
88. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.
Wudhikarn K; Palomba ML; Pennisi M; Garcia-Recio M; Flynn JR; Devlin SM; Afuye A; Silverberg ML; Maloy MA; Shah GL; Scordo M; Dahi PB; Sauter CS; Batlevi CL; Santomasso BD; Mead E; Seo SK; Perales MA
Blood Cancer J; 2020 Aug; 10(8):79. PubMed ID: 32759935
[TBL] [Abstract][Full Text] [Related]
89. Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
Karschnia P; Rejeski K; Winkelmann M; Schöberl F; Bücklein VL; Blumenberg V; Schmidt C; Blobner J; von Bergwelt-Baildon M; Tonn JC; Kunz WG; Subklewe M; von Baumgarten L
Neurology; 2022 May; 98(21):884-889. PubMed ID: 35351785
[TBL] [Abstract][Full Text] [Related]
90. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
Wright CM; LaRiviere MJ; Baron JA; Uche C; Xiao Y; Arscott WT; Anstadt EJ; Barsky AR; Miller D; LaRose MI; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Paydar I; Maity A; Plastaras JP
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):178-188. PubMed ID: 32446950
[TBL] [Abstract][Full Text] [Related]
91. Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center.
Chacim S; Monjardino T; Cunha JL; Medeiros P; Redondo P; Bento MJ; Mariz JM
PLoS One; 2022; 17(12):e0278950. PubMed ID: 36490296
[TBL] [Abstract][Full Text] [Related]
92. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
93. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Wang Y; Jain P; Locke FL; Maurer MJ; Frank MJ; Munoz JL; Dahiya S; Beitinjaneh AM; Jacobs MT; Mcguirk JP; Vose JM; Goy A; Andreadis C; Hill BT; Dorritie KA; Oluwole OO; Deol A; Paludo J; Shah B; Wang T; Banerjee R; Miklos DB; Rapoport AP; Lekakis L; Ghobadi A; Neelapu SS; Lin Y; Wang ML; Jain MD
J Clin Oncol; 2023 May; 41(14):2594-2606. PubMed ID: 36753699
[TBL] [Abstract][Full Text] [Related]
94. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
95. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
Hayden PJ; Roddie C; Bader P; Basak GW; Bonig H; Bonini C; Chabannon C; Ciceri F; Corbacioglu S; Ellard R; Sanchez-Guijo F; Jäger U; Hildebrandt M; Hudecek M; Kersten MJ; Köhl U; Kuball J; Mielke S; Mohty M; Murray J; Nagler A; Rees J; Rioufol C; Saccardi R; Snowden JA; Styczynski J; Subklewe M; Thieblemont C; Topp M; Ispizua ÁU; Chen D; Vrhovac R; Gribben JG; Kröger N; Einsele H; Yakoub-Agha I
Ann Oncol; 2022 Mar; 33(3):259-275. PubMed ID: 34923107
[TBL] [Abstract][Full Text] [Related]
96. Infectious complications among CD19 CAR-T cell therapy recipients: A single-center experience.
Walker B; Zimmer AJ; Stohs EJ; Lunning M; Lyden E; Abbas A
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14191. PubMed ID: 37987114
[TBL] [Abstract][Full Text] [Related]
97. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).
Vic S; Thibert JB; Bachy E; Cartron G; Gastinne T; Morschhauser F; Le Bras F; Bouabdallah K; Despas F; Bay JO; Rubio MT; Mohty M; Casasnovas O; Choquet S; Castilla-Llorente C; Guidez S; Loschi M; Guffroy B; Carras S; Drieu La Rochelle L; Guillet M; Houot R
Blood Adv; 2024 Mar; 8(6):1573-1585. PubMed ID: 38181767
[TBL] [Abstract][Full Text] [Related]
98. Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR).
Galli E; Viscovo M; Fosso F; Pansini I; Di Cesare G; Iacovelli C; Maiolo E; Sorà F; Hohaus S; Sica S; Bellesi S; Chiusolo P
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473919
[TBL] [Abstract][Full Text] [Related]
99. Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders.
Bachanova V; Nachman PH
Bone Marrow Transplant; 2023 Nov; 58(11):1175-1176. PubMed ID: 37598289
[No Abstract] [Full Text] [Related]
100. Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737-2746.
Blood; 2023 Feb; 141(6):683. PubMed ID: 36757722
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
